Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer
Open Access
- 28 October 2009
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Virology Journal
- Vol. 3 (1) , 67-83
Abstract
Cervical cancer and its precursor intra-epithelial lesions are linked to infection by a subset of so-called "highrisk" human papillomavirus types, which are estimated to infect nearly four hundred million women worldwide. Two prophylactic vaccines have been commercialized recently targeting HPV16 and 18, the most prevalent viral types found in cervical cancer, which operate through induction of capsid-specific neutralizing antibodies. However, in patients with persistent infection these vaccines have not been found to protect against progression to neoplasia. Attempts are being made to develop therapeutic vaccines targeting nonstructural early viral proteins. Among these, E6 and E7 are the preferred targets, since they are essential for induction and maintenance of the malignant phenotype and are constitutively expressed by the transformed epithelial cells. Here are reviewed the most relevant potential vaccines based on HPV early antigens that have shown efficacy in preclinical models and that are being tested in clinical studies, which should determine their therapeutic capacity for eradicating HPV-induced premalignant and malignant lesions and cure cervical cancer.Keywords
This publication has 99 references indexed in Scilit:
- Human Papillomavirus Type 16 E7 Oncoprotein Associates with the Centrosomal Component γ-TubulinJournal of Virology, 2007
- Association of cervical cancer with the presence of CD4+regulatory T cells specific for human papillomavirus antigensProceedings of the National Academy of Sciences, 2007
- Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patientsArchives of Virology, 2006
- Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus modelVaccine, 2005
- Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patientsJournal of Cancer Research and Clinical Oncology, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Immune evasion in human papillomavirus-associated cervical cancerNature Reviews Cancer, 2002
- Papillomavirus Type 16 Oncogenes Downregulate Expression of Interferon-Responsive Genes and Upregulate Proliferation-Associated and NF-κB-Responsive Genes in Cervical KeratinocytesJournal of Virology, 2001
- Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypesSeminars in Cancer Biology, 1999
- Papillomavirus infections — a major cause of human cancersBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1996